Brief: Hugel Resubmits BLA For Its Botulinum Toxin, Letybo To The U.S. FDA
Sept 1 (Reuters) - Hugel Inc 145020.KQ :
* HUGEL RESUBMITS BLA FOR ITS BOTULINUM TOXIN, LETYBO TO THE
U.S.
FDA
* HUGEL INC - EXPECTED TO OBTAIN U.S. FDA'S APPROVAL IN Q1
OF 2024
* HUGEL INC - RESUBMITTED BLA AFTER COMPLETING A REVIEW OF
FACILITY MANAGEMENT AND SUPPLEMENTARY WORK IN-LINE WITH CRL
REQUESTS RECEIVED FROM FDA
Source text for Eikon: ID:nPn8CgPbha
Further company coverage: 145020.KQ
Recent news on Hugel
See all newsBrief: Hugel To Cancel 54 Billion Won Worth Of Own Shares
Brief: Hugel Q3 Operating Profit 18 Billion Won, Down 62% From Year Earlier
Brief: Hugel Reports Q2 2026 Net Sales Up 25.1% TO KRW 137.90 Billion
Brief: Hugel Q4 Operating Profit 58.6 Billion Won, Up 26% From Year Earlier
Brief: Hugel Q3 Operating Profit 47.4 Billion Won, Down 11% From Year Earlier